Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Value of the tumor inhibitor of cellular immunity PDL-1 in the incidence of veno...
Journal Information
Vol. 162. Issue 9.
Pages 425-427 (May 2024)
Download PDF
More article options
Vol. 162. Issue 9.
Pages 425-427 (May 2024)
Original article
Value of the tumor inhibitor of cellular immunity PDL-1 in the incidence of venous thrombosis in patients with gastric cancer
Valor del inhibidor tumoral de la inmunidad celular PDL-1 en la incidencia de trombosis venosa en pacientes con cáncer gástrico
Margarita Lorentea, Kevin Doelloa,b,
Corresponding author

Corresponding author.
a Servicio de Oncología Médica, Hospital Virgen de las Nieves, Granada, Spain
b Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain
Article information
Full Text
Download PDF
Tables (3)
Table 1. Descriptive statistics (absolute and relative frequencies) on the oncological characteristics of the patients studied.
Table 2. Descriptive statistics (absolute and relative frequencies) on the characteristics of venous thrombosis in the patients studied.
Table 3. Summary table of the relative and absolute frequency of occurrence of venous thromboembolic events stratified by the different variables analyzed.
Show moreShow less

Gastric cancer is one of the cancers most associated with thromboembolic phenomena. The objective of this article is to study if there is a correlation between thromboembolic phenomena in gastric cancer and tumor expression of PDL-1.


To this end, the association between thromboembolic events and PDL-1 expression was retrospectively studied in a sample of 46 patients from our hospital.


The results obtained revealed a statistically significant difference between the percentage of thromboembolic events between positive and negative PDL-1 with an increase in the latter with a P value of 0.034.


In conclusion, the expression of PDL-1, and with it, of an inhibitory factor of the cellular immune response, correlates with a decrease in thromboembolic events in patients with gastric cancer, which could indicate the crucial role of the immune response in which thromboembolic events occur.

Gastric cancer
Cellular immunity
Thromboembolic events

El cáncer gástrico es uno de los cánceres más asociados a fenómenos tromboembólicos. El objetivo de este artículo es estudiar si existe correlación entre los fenómenos tromboembólicos en el cáncer gástrico y la expresión tumoral de PDL-1.


Para ello, se estudió retrospectivamente la asociación entre eventos tromboembólicos y la expresión de PDL-1 en una muestra de 46 pacientes de nuestro hospital.


Los resultados obtenidos revelaron una diferencia estadísticamente significativa entre el porcentaje de eventos tromboembólicos entre PDL-1 positivo y negativo con un aumento en este último con un valor P de 0,034.


La expresión de PDL-1, y con ella, de un factor inhibidor de la respuesta inmune celular, se correlaciona con una disminución de los eventos tromboembólicos en pacientes con cáncer gástrico, lo que podría indicar el papel crucial de la respuesta inmune en la ocurrencia de eventos tromboembólicos.

Palabras clave:
Cáncer gástrico
Inmunidad celular
Eventos tromboembólicos


These are the options to access the full texts of the publication Medicina Clínica (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Medicina Clínica (English Edition)

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos